luciddx.com - LUCD Total Company Value-to-Revenue Ratio

Public company logo of luciddx.com (LUCD)

Lucid Diagnostics Inc. (LUCD) management effectively engages with insurance companies, ensuring data transparency for EsoGuard. Business revenues are based on the sale of diagnostic tests for precancerous esophageal conditions to patients with GERD. Scaling analysis systems creates a foundation for stable growth. The EV/Sales valuation demonstrates price dynamics relative to revenue, where 14788.60 determines the latest valuation metric.

LUCD: Lucid Diagnostics, Inc Company Value to Revenue 11/23/2025 - 11/20/2026

Lucid Diagnostics, Inc - analytical breakdowns and key metrics (LUCD)

Fundamental company valuation:LUCD - Lucid Diagnostics Inc.
Finished products of Lucid Diagnostics Inc

Analyzing the enterprise value-to-revenue ratio on GURU.Markets, we determine the market status of Lucid Diagnostics Inc. (LUCD) within the diagnostics sector. This indicator compares the total value of the business against its revenues, eliminating the impact of debt loads and tax distortions. The metric measures the capitalization efficiency of each unit of revenue. However, the geopolitical fragmentation of healthcare limits test exports, creating pressure on this ratio. The stability of the chart confirms current resilience but limits expansion potential.

Competitor analysis for Lucid Diagnostics Inc.

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue